For starters, CIMB Research maintains its “reduce” rating on the stock with an unchanged price target of $1.46, noting negative earnings growth in terms of fourth quarter results.
SINGAPORE (Feb 21): The research houses of CIMB, RHB and DBS are reiterating their divided opinions on Raffles Medical Group after it on Monday reported a 1.3% rise in FY16 earnings to $70.2 million on higher revenue.
(See also: Raffles Medical’s FY16 earnings rise 1.3% to $70.2 mil on higher revenue)
